Poster Abstract Session:
77. Vaccines: Pediatric
Thursday, October 27, 2016: 12:30 PM-2:00 PM
Room: Poster Hall

Tracks: Pediatric ID

Presentations:
755
Posters
  • CHE.Close.Pearson.Cohn.pdf (359.8 kB)
  • 757
    Varicella Vaccination in the United States – Two Decades of Experience with Program Implementation
    Mona Marin, MD ; Adriana S. Lopez, MHS ; Jessica Leung, MPH ; D. Scott Schmid, PhD ; Rafael Harpaz, MD, MPH
    Posters
  • IDWeek 2016_Var_vax in US.pdf (524.3 kB)
  • 759
    Impact of Universal Immunization Policy on Childhood Influenza Vaccination Rates in Children With and Without High-Risk Conditions in the United Kingdom
    Herve Caspard, MD, ScD ; Amy Steffey, DVM, MPH ; Betina Blak, PhD ; Sankarasubramanian Rajaram, MD, MBA
    760
    Detection of Oseltamivir Resistance in Influenza Viruses: Insights from a Ferret Model
    Larisa Gubareva, MD, PhD ; Henju Marjuki, Ph.D. ; Vasiliy Mishin, PhD ; Anton Chesnokov, MS ; Juan a. De La Cruz, M.S. ; Alicia M. Fry, MD, MPH
    761
    Randomized Study To Compare Immunogenicity And Safety Of Seqirus* Quadrivalent Inactivated Influenza Vaccine With A US-Registered Influenza Vaccine In Paediatric Subjects Aged 5 To 17 Years
    Jane Leong, MBBS, FRACGP, MBA ; Daphne Sawlwin, MBBS, BMEDSC (IMMUNOLOGY), MSC (CLINICAL EPIDEMIOLOGY) ; Alison Graves-Jones, MPH ; Neil Formica, MBBS MPH MAppEpid ; Jolanta Airey, MD ; Frank Albano, PhD, MBA
    762
    Disease Burden Associated with ICD-9 Diagnosed Influenza and Related Complications in US Children Aged 6-35 Months
    Philip Buck, PhD, MPH ; David Smith, PhD ; Rahul Shenolikar, PhD ; Debra Irwin, PhD, MSPH
    763
    Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine (NBP607-QIV) in South Korean children and adolescents: A randomized, double-blind, multi-center, phase 3 clinical trial
    Yun-Kyung Kim, MD, PhD ; Byung Wook Eun, MD, PhD ; Taek Jin Lee, M.D. ; Jina Lee, MD, PhD ; Ki Hwan Kim, M.D. ; Dong Ho Kim, MD ; Dae Sun Jo, M.D., Ph.D. ; Sun-Hee Shin, MD
    Posters
  • IDWeek2016_Session77_763.pdf (593.0 kB)
  • 765
    Determinants of Rotavirus Acquisition in Rotavirus-Vaccinated Guatemalan Infants
    James Gaensbauer, MD, MScPH ; Mario Melgar, MD ; Mirella Calvimontes, MD ; Edwin J Asturias, MD ; Ingrid Contreras-Roldan, MD ; Samuel R. Dominguez, MD, PhD ; Christine C. Robinson, PhD ; Satoshi Kamidani, MD ; Stephen Berman, MD
    767
    Description of children hospitalized with vaccine preventable diseases in Central Pennsylvania
    Gregory Williamson, BS ; Bilaal Ahmed, MPH ; Parvathi Kumar, MD ; Jessica E Ericson, MD
    768
    What's happening with Haemophilus influenzae type b invasive disease in Latin America Region? Argentina's experience.
    Maria Del Valle Juarez, MD ; Carolina Rancaño, MD ; Silvina Neyro, MD ; Cristian Biscayart, MD ; Nathalia Katz, MD ; Marina Pasinovich, MD ; Marcela Lopez Yunes, MD ; Analia Aquino, PharmD ; Carla Vizzotti, MD
    769
    Is Haemophilus influenzae type b (Hib) reemerging? 24 years of meningitis surveillance in a Pediatric Hospital in Buenos Aires metropolitan area.
    Angela Gentile, MD ; Maria Florencia Lucion, MD ; Ana Clara Martinez, MD ; Maria Del Valle Juarez, MD ; Candela Burgo Gonzalez, MD ; Maria Paula Della Latta, MD ; Viviana Romanin, MD ; Julia Bakir, MD ; Marisa Turco, Biochemistry
    770
    The Role of Antibodies to Neisserial Heparin binding antigen (NHba) in Protection Elicited by the MenB-4C Vaccine
    Elizabeth Partridge, MD, MPH ; Serena Giuntini, PhD ; Eduardo Lujan, MS ; Dan M. Granoff, MD
    Posters
  • Final_EP_ID Week Poster.pdf (885.5 kB)
  • 771
    Use of Internet Search Data to Monitor Rotavirus Vaccine Impact in the United States, United Kingdom and Mexico
    Minesh Shah, MD, MPH ; Benjamin Lopman, PhD, MSc ; Jacqueline Tate, PhD ; John Harris Jr., MD ; Marcelino Esparza-Aguilar, MD, MSc ; Edgar Sanchez-Uribe, MD ; Vesta Richardson, MD ; Umesh D. Parashar, MBBS, MPH

    CME Credits: No CME credit is offered for this session.

    ACPE Credits:

    ACPE Number:


    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.